S-OA-N Oral Abstracts - Session N - Leukemia & Immune Reconstitution

Track: BMT Tandem "Scientific" Meeting
Sunday, February 15, 2015: 10:30 AM-12:00 PM
Seaport Ballroom DE (Manchester Grand Hyatt)
Chairs:
Miguel-Angel Perales, MD and Carlos A. Ramos, MD

Disclosures:
M. A. Perales, Astellas, Ad Board: Advisory Board and Honoraria
Merck, Ad Board: Advisory Board and Honoraria
ImmunID, Scientific Advisory Board: Advisory Board and Honoraria

C. A. Ramos, Nothing To Disclose

74
Comparing the Results of Non-TBI Hematopoietic Stem Cell Transplantation in Pediatric Patients with Acute Lymphoblastic Leukemia (ALL) with and without CNS Involvement
Amir Ali Hamidieh, M.D., Tehran University of Medical Sciences; Maryam Kabootari, M.D., Tehran University of Medical Sciences; Mohsen Esfandbod, M.D., Tehran University of Medical Sciences; Maryam Behfar, M.D., Tehran University of Medical Sciences; Arash Jalali, Tehran University of Medical Sciences; Ardeshir Ghavamzadeh, M.D., Tehran University of Medical Sciences

75
Safety and Efficacy of Ibrutinib in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Who Have Undergone Prior Allogeneic Stem Cell Transplant
David B. Miklos, Stanford University School of Medicine; Steven Coutre, Stanford University School of Medicine; Susan O'Brien, MD, MD Anderson Cancer Center; John C. Byrd, MD, The Ohio State University Medical Center; Peter Hillmen, MD, PhD, FRCP, FRCPath, The Leeds Teaching Hospitals, St. James Institute of Oncology; Jennifer R. Brown, MD, PhD, Dana-Farber Cancer Institute; Martin Dyer, MA, DPhil, FRCP, FRCPath, University of Leicester; Anthony R. Mato, MD, Hackensack University Medical Center; Michael Keating, MBBS, MD Anderson Cancer Center; Cathy Zhou, MS, Pharmacyclics, Inc.; Maria Fardis, PhD, MBA, Pharmacyclics, Inc.; Lori Styles, MD, Pharmacyclics, Inc.; Samantha Jaglowski, MD, MPH, The Ohio State University Medical Center

76
Allogeneic Transplant for Acute Biphenotypic Leukemia: Characteristics and Outcome in the CIBMTR Database
Reinhold Munker, MD, Louisiana State University Health Shreveport; Hai-Lin Wang, MPH, Medical College of Wisconsin; Ruta Brazauskas, PhD, Medical College of Wisconsin; Wael Saber, MD, MS, Medical College of Wisconsin; Daniel J. Weisdorf, MD, University of Minnesota Medical Center

54
Exhaustive TCR Deep Sequencing Reveals That CMV Reactivation Fundamentally Resets Immune Reconstitution after Transplant and Results in Significant Deficits in the Effector Memory TCR Repertoire
Yvonne Suessmuth, Emory University; Divya Koura, Emory University; Knut Finstermeier, Adaptive Biotechnologies; Cindy Desmarais, PhD, AdaptiveTCR; John Horan, MD, MPH, Columbia University Medical Center; Amelia Langston, MD, Emory University School of Medicine; Muna Qayed, MD, Emory University; H. Jean Khoury, MD, Emory University School of Medicine; Benjamin K. Watkins, MD, Emory University; Harlan Robins, PhD, Adaptive TCR; Rithun Mukherjee, Seattle Children's Research Institute; Bruce R. Blazar, MD, University of Minnesota; Edmund K. Waller, MD, PhD, Emory University; Aneesh Mehta, Emory University; Leslie S. Kean, MD, PhD, Fred Hutchinson Cancer Research Center

55
Comparable and Robust Immune Reconstitution after HLA-Haploidentical or HLA-Matched Allogeneic Transplantation (BMT) Utilizing Posttransplantation Cyclophosphamide
Shannon R. McCurdy, MD, The Johns Hopkins University School of Medicine; Ante Vulic, MD, The Johns Hopkins University School of Medicine; Heather J. Symons, MD, MHS, The Johns Hopkins University School of Medicine; Andrea M. Towlerton, BS, Fred Hutchinson Cancer Research Center; Ben C. Valdez, PhD, UT M.D. Anderson Cancer Center; Richard J. Jones, MD, The Johns Hopkins University; Ephraim J. Fuchs, MD, MBA, Johns Hopkins University School of Medicine; Paul V. O'Donnell, MD, PhD, FACP, Fred Hutchinson Cancer Research Center; Edus H. Warren, MD, PhD, Fred Hutchinson Cancer Research Center; Christopher G. Kanakry, MD, The Johns Hopkins University School of Medicine; Leo Luznik, MD, The Johns Hopkins University School of Medicine

56
CD4+FoxP3+ Regulatory T Cells Promote B Cell Differentiation and Induce Tolerance to Bone Marrow Grafts
Antonio Pierini, MD, Stanford University; Hidekazu Nishikii, MD, PhD, Stanford University; Yuqiong Pan, MD, PhD, Stanford University; Jeanette Baker, PhD, Stanford University; Dominik Schneidawind, MD, Stanford University; Maite Alvarez, PhD, Stanford University; Robert Negrin, MD, Stanford University Medical Center